GnRH analogue + dydrogesterone + letrozole

This is a combination therapy consisting of a gonadotropin-releasing hormone (GnRH) analogue, dydrogesterone, and letrozole. Each component has a distinct mechanism of action: - **GnRH analogue** suppresses pituitary gonadotropin secretion, leading to decreased ovarian estrogen production. - **Dydrogesterone** is a synthetic progestogen that mimics endogenous progesterone activity and modulates the endometrial response to estrogen. - **Letrozole** is an aromatase inhibitor that blocks the conversion of androgens to estrogens, further reducing circulating estrogen levels. This combination targets multiple hormonal pathways involved in reproductive endocrinology. While combinations such as letrozole plus dydrogesterone have been studied for endometriosis[1][3], and GnRH analogues with letrozole have been used in breast cancer[2] or ovarian stimulation protocols[4], there are no published studies specifically evaluating all three agents together as a single regimen. The rationale for combining these drugs would be to achieve more profound suppression of estrogen-driven conditions (such as endometriosis or certain hormone-sensitive cancers) by acting at different points in the hypothalamic-pituitary-gonadal axis.